BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

...Phase I for rheumatoid arthritis. " title="Interactive or visual content" frameborder="0" scrolling="no" style="width:100%;height:750px;"> KT-474 from Kymera Therapeutics...
...family zinc finger 1 (IKAROS) (IKZF1) (LYF1)IRAK4 – Interleukin-1 receptor-associated kinase 4 Danielle Golovin PF-06650808 R835 Pfizer Inc. Rigel Pharmaceuticals Inc. Kymera Therapeutics...
BioCentury | Dec 22, 2020
Finance

Deerfield launches protein degradation start-up Neomorph with $109M series A

...year, with Arvinas Inc .(NASDAQ:ARVN) unveiling the first clinical efficacy data for a protein degrader; Kymera Therapeutics...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...degrader ARV-471. Three targeted protein degradation companies —Kymera Therapeutics...
BioCentury | Dec 15, 2020
Product Development

Arvinas regains investor confidence with path forward for androgen-receptor degrader, second proof of concept for platform

...protein degradation companies set to enter the clinic this year. Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), Kymera Therapeutics...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...degradation: cereblon, vHL and IAP.  Companies including Arvinas, Kymera Therapeutics...
...– von Hippel-Lindau tumor suppressor Karen Tkach Tuzman Arvinas Inc. Kymera Therapeutics...
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

...performance is in line with two other protein degradation companies that went public this summer: Kymera Therapeutics...
BioCentury | Aug 29, 2020
Management Tracks

Bi’s back; plus changes at Kymera, Immunovia, Apic, Vor, Organogenesis and more

...Medical Products Administration), but resigned in March 2018 amid a vaccines manufacturing scandal (see “Thinking Beyond Bi”).Kymera Therapeutics...
...a new position. She joined the hematological malignancies company in 2017 as director of operations. Robin Sawka Kymera Therapeutics...
BioCentury | Aug 22, 2020
Emerging Company Profile

Amphista: broadening the target space of protein degradation

...upfront and most advanced partnered protein degradation asset to date, with Sanofi (Euronext:SAN; NASDAQ:SNY) paying Kymera Therapeutics...
...None issued Danielle Golovin Amphista Therapeutics Ltd. University of Dundee Advent Life Sciences Scottish Investment Bank Scottish Growth Scheme European Investment Fund BioMotiv Arvinas Inc. Kymera Therapeutics...
BioCentury | Aug 22, 2020
Finance

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...BCIQ database (see “Preclinical IPOs Attracting Big Money”). Kymera Therapeutics...
...receptor 2IRAK4 – Interleukin-1 receptor-associated kinase 4 Paul Bonanos Kymera Therapeutics...
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

...once the deals are complete (see “Kidney Play Chinook Rounds Out Pipeline”).Kymera sets IPO termsIf Kymera Therapeutics...
...member 2 BC Staff P-PSMA-101 Goofice (Brand), AJG533 (Compound #), A3309 (Compound #), elobixibat (Generic) Poseida Therapeutics Inc. Albireo Pharma Inc. Kymera Therapeutics Chinook...
Items per page:
1 - 10 of 47
BioCentury | Jan 5, 2021
Product Development

IRAK4 inhibitor pipeline: Data Byte

...Phase I for rheumatoid arthritis. " title="Interactive or visual content" frameborder="0" scrolling="no" style="width:100%;height:750px;"> KT-474 from Kymera Therapeutics...
...family zinc finger 1 (IKAROS) (IKZF1) (LYF1)IRAK4 – Interleukin-1 receptor-associated kinase 4 Danielle Golovin PF-06650808 R835 Pfizer Inc. Rigel Pharmaceuticals Inc. Kymera Therapeutics...
BioCentury | Dec 22, 2020
Finance

Deerfield launches protein degradation start-up Neomorph with $109M series A

...year, with Arvinas Inc .(NASDAQ:ARVN) unveiling the first clinical efficacy data for a protein degrader; Kymera Therapeutics...
BioCentury | Dec 18, 2020
Product Development

2021 Predictions: a BioCentury survey

...degrader ARV-471. Three targeted protein degradation companies —Kymera Therapeutics...
BioCentury | Dec 15, 2020
Product Development

Arvinas regains investor confidence with path forward for androgen-receptor degrader, second proof of concept for platform

...protein degradation companies set to enter the clinic this year. Shares of C4 Therapeutics Inc. (NASDAQ:CCCC), Kymera Therapeutics...
BioCentury | Oct 23, 2020
Product Development

What’s next for targeted protein degradation

...degradation: cereblon, vHL and IAP.  Companies including Arvinas, Kymera Therapeutics...
...– von Hippel-Lindau tumor suppressor Karen Tkach Tuzman Arvinas Inc. Kymera Therapeutics...
BioCentury | Oct 2, 2020
Finance

C4 is latest preclinical protein degradation IPO with big aftermarket gain

...performance is in line with two other protein degradation companies that went public this summer: Kymera Therapeutics...
BioCentury | Aug 29, 2020
Management Tracks

Bi’s back; plus changes at Kymera, Immunovia, Apic, Vor, Organogenesis and more

...Medical Products Administration), but resigned in March 2018 amid a vaccines manufacturing scandal (see “Thinking Beyond Bi”).Kymera Therapeutics...
...a new position. She joined the hematological malignancies company in 2017 as director of operations. Robin Sawka Kymera Therapeutics...
BioCentury | Aug 22, 2020
Emerging Company Profile

Amphista: broadening the target space of protein degradation

...upfront and most advanced partnered protein degradation asset to date, with Sanofi (Euronext:SAN; NASDAQ:SNY) paying Kymera Therapeutics...
...None issued Danielle Golovin Amphista Therapeutics Ltd. University of Dundee Advent Life Sciences Scottish Investment Bank Scottish Growth Scheme European Investment Fund BioMotiv Arvinas Inc. Kymera Therapeutics...
BioCentury | Aug 22, 2020
Finance

Enthusiasm for protein degradation, preclinical IPOs gives Kymera first-day pop

...BCIQ database (see “Preclinical IPOs Attracting Big Money”). Kymera Therapeutics...
...receptor 2IRAK4 – Interleukin-1 receptor-associated kinase 4 Paul Bonanos Kymera Therapeutics...
BioCentury | Aug 19, 2020
Finance

Aug. 18 Quick Takes: Chinook fuels up for NASDAQ liftoff; plus Kymera, Poseida, Albireo

...once the deals are complete (see “Kidney Play Chinook Rounds Out Pipeline”).Kymera sets IPO termsIf Kymera Therapeutics...
...member 2 BC Staff P-PSMA-101 Goofice (Brand), AJG533 (Compound #), A3309 (Compound #), elobixibat (Generic) Poseida Therapeutics Inc. Albireo Pharma Inc. Kymera Therapeutics Chinook...
Items per page:
1 - 10 of 47